Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Fibroblasts undergoing replicative senescence or transforming growth factor β1-induced senescence and fibroblasts isolated from human subjects with an age-related lung disorder, idiopathic pulmonary fibrosis, secreted higher numbers of EVs than their respective controls.
|
30321056 |
2019 |
Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapies, and transforming growth factor-β1 (TGF-β1) plays a central role in the pathogenesis of IPF.
|
31606345 |
2019 |
Lung diseases
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of TGF-β1 are found in patients with acute and chronic lung diseases, and the underlying disease processes are exacerbated by respiratory viral infections.
|
29427413 |
2018 |
Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
While the serum and BALF levels of KL-6 and TGF-β2 are not highly specific, TGF-β1 may be a valuable reference diagnostic marker in HM lung disease.
|
29669483 |
2018 |
Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
The significant Ago2-IP enrichment of targets of these miRNAs related to the TGF-β and/or Wnt pathways (NGF, DLD, HHEX) in TGF-β1-stimulated fibroblasts suggest a role for these miRNAs in lung diseases by affecting lung fibroblast function.
|
28910321 |
2017 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
High-producer TGFβ1 genotypes are associated with severe lung disease in cystic fibrosis (CF), but studies combining IL-8, TNFα-, and TGFβ1(+genotype) levels and their impact on CF lung disease are scarce.
|
24062613 |
2013 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In contrast, pathogenesis of other chronic lung diseases like ΔF508-cystic fibrosis (CF), α1-anti-trypsin-deficiency (α-1 ATD) and pulmonary fibrosis (PF) is regulated by other proteostatic mechanisms, involving the degradation of misfolded proteins (ΔF508-CFTR/α1-AT- Z variant) or regulating the concentration of signaling proteins (such as TGF-β1) by the ubiquitin-proteasome system (UPS).
|
22697347 |
2012 |
Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
These data suggest that the beneficial anti-fibrotic effects of SAP in TGFβ(1)-induced lung disease are via modulating monocyte responses.
|
21044893 |
2011 |
Lung diseases
|
0.600 |
Biomarker
|
group |
RGD |
Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-beta1-Smad2 dependent pathway.
|
19941153 |
2010 |
Lung diseases
|
0.600 |
Biomarker
|
group |
RGD |
Pyrrolidine dithiocarbamate attenuates paraquat-induced lung injury in rats.
|
19639047 |
2009 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In summary, the results confirm the hypothesis that TGF-beta1 polymorphisms are associated with asbestos-induced fibrotic or malignant lung diseases in whites.
|
19349911 |
2009 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Analysis of the T869C polymorphism in the TGF-beta1 gene showed an association only between TC heterozygotes and mild pulmonary disease.
|
19466271 |
2009 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These findings support the concept that TGFB1 gene variants appear to be important genetic modifiers of lung disease progression in CF.
|
19009622 |
2008 |
Lung diseases
|
0.600 |
Biomarker
|
group |
LHGDN |
These findings provide evidence of gene-gene interaction in the pathogenesis of CF lung disease, whereby high TGF-beta1 production enhances the modulatory effect of MBL2 on the age of first bacterial infection and the rate of decline of pulmonary function.
|
18292811 |
2008 |
Lung diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
These results demonstrate that TGFB1 is a modifier of CF lung disease and reveal a previously unrecognized beneficial effect of TGFB1 variants upon the pulmonary phenotype.
|
18424453 |
2008 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
TGF-beta1, a cytokine involved in mediating the fibrotic/Th1 response, has several genetic variants which might predispose individuals to these lung diseases.
|
17785866 |
2007 |
Lung diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Emerging data indicate that non-CFTR genetic variants contribute to at least half the variability in pulmonary disease severity, and genetic variation in transforming growth factor beta1 clearly modifies the severity of cystic fibrosis lung disease.
|
17053491 |
2006 |
Lung diseases
|
0.600 |
AlteredExpression
|
group |
BEFREE |
This study examined whether or not components of the Shh signalling pathway, as well as TGF-beta1, are expressed in human fibrotic lung disease (cryptogenic fibrosing alveolitis and bronchiectasis) and in murine experimental models of fibrotic and non-fibrotic chronic pulmonary inflammation.
|
12635140 |
2003 |
Lung diseases
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Two anti-inflammatory cytokines, interleukin-1 receptor antagonist and transforming growth factor-beta1, had increased expression, consistent with other human fibrotic lung diseases and animal models of lung fibrosis.
|
11970906 |
2002 |
Lung diseases
|
0.600 |
Biomarker
|
group |
CTD_human |
Before these experiments, there was no information available that would provide a basis for predicting whether or not TGF-beta(1) expression induces fibroproliferative lung disease in fibrogenic-resistant TNF-alphaRKO mice, an increasingly popular animal model.
|
11472967 |
2001 |